GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Manhattan Scientifics MHTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

0.00%

Close of 6 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

—

FY2014FY2023

Net income

−$1.2m

FY2014FY2023

Free cash flow

−$190,000

FY2014FY2023

Shareholders' equity

−$1.8m

FY2014FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue—$50,000$50,000$50,000$97,000—$142,000$150,000$64,000$642,000
Research and development$10,000$11,000$10,000$11,000$8,000$52,000$175,000$3.3m$2.9m$1.9m
Operating income−$703,000−$679,000−$687,000−$675,000−$1.0m−$1.4m−$2.3m−$6.4m−$6.3m−$3.5m
Net income−$1.2m−$2.7m−$3.6m$4.3m−$1.2m−$8.3m$1.5m−$6.1m$8.0m−$3.8m
Diluted earnings per share-0.00-0.00-0.010.01-0.00-0.020.00-0.010.01-0.01

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$316,000$1.0m$3.5m$6.8m$2.2m$2.7m$10.8m$7.6m$12.9m$3.6m
Cash and short-term investments$67,000$175,000$232,000$353,000$261,000$87,000$269,000$1.1m$5.4m$2.5m
Total liabilities$2.1m$2.7m$2.4m$2.2m$3.2m$2.8m$2.7m$4.9m$4.3m$4.5m
Debt$60,000$110,000$130,000$104,000$78,000——$2.4m$2.4m$3.0m
Shareholders' equity−$1.8m−$1.7m$1.0m$4.7m−$1.0m−$150,000$8.2m$2.7m$8.6m−$832,000
Shares outstanding559m559m559m559m558m534m534m534m537m508m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$190,000−$349,000−$421,000−$388,000−$316,000−$682,000−$791,000−$4.6m$3.4m−$2.5m
Capital spending———−$4,000−$4,000−$4,000−$8,000−$13,000−$255,000−$36,000
Free cash flow−$190,000−$349,000−$421,000−$392,000−$320,000−$686,000−$799,000−$4.6m$3.2m−$2.6m

Latest quarters

By quarter end

Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022
Revenue—$2,000———−$50,000—$9,000
Operating income−$160,000−$192,000−$151,000−$180,000−$186,000−$186,000−$174,000−$168,000
Net income−$158,000−$382,000−$254,000−$262,000−$229,000−$420,000−$396,000−$71,000
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$74,000$91,000$316,000$432,000$569,000$694,000$1.0m$1.4m
Cash and short-term investments$38,000$51,000—$89,000$52,000$90,000—$288,000
Debt$60,000$60,000—$60,000$70,000$70,000—$139,000
Shareholders' equity−$2.3m−$2.2m−$2.9m−$2.6m−$2.3m−$2.1m−$1.7m−$1.3m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income1.4%-13.5%-9.0%
Net income—-32.5%-4.9%

Valuation history

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2017FY2016FY2015FY2014FY2013
Price to earnings-0.0-0.0-0.00.1-0.10.1-0.00.0-0.1-0.1
Price to sales—1.42.87.30.90.61.24.00.60.3

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-86%62%-30%-60%-50%208%136%-40%-33%-53%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.